{"rows":[{"id":5946,"title":"Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants.","authors":"Signor A, Comai S, Pasut G, Folli F, Gentilucci M, Gharavi N, Raitsin S, Van Nguyen T, Pappagallo M, Mattarei A, Manfredi PL, De Martin S.","journal":"British journal of clinical pharmacology","publication_date":"2026-09-21","publication_year":2026,"doi":"10.1002/bcp.70839","pubmed_id":"42767271","openalex_id":"https://openalex.org/W7213916889","source_url":"https://doi.org/10.1002/bcp.70839","substance_tags":"psilocybin,psilocin","topic_tags":"Pharmacology,Clinical Trial,Animal Study,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-22 01:20:18","last_checked":"2026-09-28 01:20:29","bibtex":null,"source_record_id":"PMID:42767271","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1002/bcp.70839","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42767271","source_url":"https://doi.org/10.1002/bcp.70839","doi":"10.1002/bcp.70839","pmid":"42767271","publication_date":"2026-09-21","importer_version":"2.1.3","text_redistributed":false}},{"id":5740,"title":"Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations.","authors":"Cervera-Sanchez MB, San-Juan D, Díaz-Peregrino R, Camacho-Castillo EZ, Bringas-Ortiz SA, Padilla-Cabezutd C","journal":"British journal of clinical pharmacology","publication_date":"2026-10-01","publication_year":2026,"doi":"10.1002/bcp.70690","pubmed_id":"42482371","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/42482371/","substance_tags":"psilocybin","topic_tags":"Receptor Pharmacology,Clinical Trial,Review Article,Animal Study,Safety","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-23 01:20:05","last_checked":"2026-10-08 01:20:09","bibtex":null,"source_record_id":"PMID:42482371","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/42482371/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:42482371","source_url":"https://pubmed.ncbi.nlm.nih.gov/42482371/","doi":"10.1002/bcp.70690","pmid":"42482371","publication_date":"2026-10-01","importer_version":"2.1.3","text_redistributed":false}},{"id":1392,"title":"Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins.","authors":"Szigeti B, Phillips LD, Nutt D","journal":"British journal of clinical pharmacology","publication_date":"2023-09-01","publication_year":2023,"doi":"10.1111/bcp.15841","pubmed_id":"37455605","openalex_id":"https://openalex.org/W4384493160","source_url":"https://pubmed.ncbi.nlm.nih.gov/37455605/","substance_tags":"psilocybin","topic_tags":"Depression,Randomized Controlled Trial","study_type":"Randomized Controlled Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:48:05","last_checked":"2026-08-09 08:28:13","bibtex":null,"source_record_id":"PMID:37455605","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/37455605/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:37455605","source_url":"https://pubmed.ncbi.nlm.nih.gov/37455605/","doi":"10.1111/bcp.15841","pmid":"37455605","publication_date":"2023-09-01","importer_version":"2.1.3","text_redistributed":false}},{"id":116,"title":"Exploring new avenues: Psychedelic-assisted therapy for young people.","authors":"Vamvakopoulou IA, Nicholls D, Nutt DJ, Di Simplicio M","journal":"British journal of clinical pharmacology","publication_date":"2026-05-08","publication_year":2026,"doi":"10.1002/bcp.70579","pubmed_id":"42101062","openalex_id":"https://openalex.org/W7160597817","source_url":"https://pubmed.ncbi.nlm.nih.gov/42101062/","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,PTSD,Wellbeing,Review Article,Observational Study,Adolescents,Safety","study_type":"Review Article","source_name":"PubMed","publication_status":"published","date_added":"2026-06-30 22:38:07","last_checked":"2026-08-09 08:27:49","bibtex":null,"source_record_id":"PMID:42101062","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/42101062/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:42101062","source_url":"https://pubmed.ncbi.nlm.nih.gov/42101062/","doi":"10.1002/bcp.70579","pmid":"42101062","publication_date":"2026-05-08","importer_version":"2.1.3","text_redistributed":false}}],"total":4,"page":1,"per_page":20,"pages":1,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"British journal of clinical pharmacology","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}